James Morris, MD
Gastroenterology · Shreveport, LANPI 1417026808
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,938 of the $11,286 with a category attached, or 70.3%. It is spread thinly across 34 manufacturers, the largest accounting for just 21.4%. Reporting peaked in 2022 at $3,657 and has fallen 74.4% since, to $935 in 2025.
Across 387 payments — averaging $29.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$2K
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Takeda Pharmaceuticals U.S.A., Inc.$853
- Johnson & Johnson$790
- Pfizer$684
- plus $2K from 28 others
Across 5 payments — averaging $14,388 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$58K
- Pfizer$14K
What the payments were for
- Speaking & faculty fees$1,50013%
- Travel & lodging$1,79116%
- Food & beverage$7,93870%
- Education$290%
- Gifts$270%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 9 | $2,413 |
| AbbVie | 122 | $2,229 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 34 | $2,076 |
| Takeda Pharmaceuticals U.S.A., Inc. | 54 | $853 |
| Johnson & Johnson | 50 | $790 |
| Pfizer | 42 | $684 |
| ERBE USA Inc | 5 | $380 |
| Gilead | 13 | $358 |
| Bristol Myers Squibb | 12 | $267 |
| Boston Scientific | 3 | $196 |
| Daiichi Sankyo Inc. | 11 | $184 |
| Janssen Scientific Affairs, LLC | 2 | $174 |
| Dendreon Pharmaceuticals LLC | 1 | $142 |
| Sanofi | 2 | $54 |
| Regeneron Healthcare Solutions, Inc. | 2 | $50 |
| Braintree Laboratories, Inc. | 3 | $45 |
| Mallinckrodt Hospital Products Inc. | 2 | $38 |
| UCB, Inc. | 2 | $37 |
| Micro-tech Endoscopy USA, Inc. | 1 | $35 |
| Laborie Medical Technologies Corp. | 1 | $27 |
| Merck | 2 | $26 |
| Dynavax Technologies Corporation | 2 | $24 |
| Progenics Pharmaceuticals, Inc. | 1 | $23 |
| Blue Earth Diagnostics | 1 | $22 |
| Evoke Pharma, Inc. | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $20 |
| Redhill Biopharma Inc. | 1 | $19 |
| Ferring Pharmaceuticals Inc. | 1 | $18 |
| Neotract Inc. | 1 | $16 |
| QOL Medical, LLC | 1 | $15 |
| Intercept Pharmaceuticals, Inc. | 1 | $13 |
| Covidien LP | 1 | $12 |
| Veran Medical Technologies, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,286 in reported general payments places this provider in the 80th percentile of 254 gastroenterology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 26 | $16,752 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 21 | $1,394 |
| Budesonide DrBudesonide | 12 | $756 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 40 | $686 |
| Esomeprazole Magnesium | 23 | $645 |
| Rabeprazole Sodium | 11 | $135 |
| Pantoprazole Sodium | 27 | $114 |
| Famotidine | 15 | $56 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $2,229 | $16,75226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 254 gastroenterology providers in Louisiana.
Other gastroenterology in Shreveport
- Humberto AguilarShreveport$313K
- Hrishikesh SamantShreveport$81K
- Sathya JaganmohanShreveport$25K
- Qiang CaiShreveport$14K
- Elvin HardyShreveport$13K
- John ProvenzaShreveport$9K
- Jonathon ChapmanBaton Rouge$998K
- Conar FittonKenner$955K
- Gia LandryBaton Rouge$511K
- Charles MonierThibodaux$448K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.